YGY Trademark

Trademark Overview

On Friday, September 21, 2007, a trademark application was filed for YGY with the United States Patent and Trademark Office. The USPTO has given the YGY trademark a serial number of 79045150. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, May 1, 2015. This trademark is owned by Laboratoire Français du Fractionnement et des; Biotechnologies. The YGY trademark is filed in the Pharmaceutical Products category with the following description:

Medicines and pharmaceutical preparations obtained from plasma or biotechnologies for the treatment of immune deficiencies and autoimmune diseases
ygy

General Information

Serial Number79045150
Word MarkYGY
Filing DateFriday, September 21, 2007
Status709 - CANCELLED - SECTION 71
Status DateFriday, May 1, 2015
Registration Number3508950
Registration DateTuesday, September 30, 2008
Mark Drawing5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, July 15, 2008

Trademark Statements

Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesMedicines and pharmaceutical preparations obtained from plasma or biotechnologies for the treatment of immune deficiencies and autoimmune diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, May 1, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameLaboratoire Français du Fractionnement et des; Biotechnologies
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressFR
Party NameLaboratoire Français du Fractionnement et des; Biotechnologies
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressFR
Party NameLaboratoire Français du Fractionnement et des; Biotechnologies
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressFR

Trademark Events

Event DateEvent Description
Friday, March 3, 2017TOTAL INVALIDATION PROCESSED BY THE IB
Saturday, March 5, 2016GENERIC MADRID TRANSACTION SENT TO IB
Saturday, March 5, 2016GENERIC MADRID TRANSACTION CREATED
Friday, January 1, 2016TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, May 1, 2015CANCELLED SECTION 71
Thursday, March 26, 2015NEW REPRESENTATIVE AT IB RECEIVED
Monday, July 21, 2014NEW REPRESENTATIVE AT IB RECEIVED
Sunday, March 31, 2013FINAL DECISION TRANSACTION PROCESSED BY IB
Wednesday, January 21, 2009FINAL DISPOSITION NOTICE SENT TO IB
Wednesday, January 21, 2009FINAL DISPOSITION PROCESSED
Wednesday, December 31, 2008FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, September 30, 2008REGISTERED-PRINCIPAL REGISTER
Tuesday, July 15, 2008PUBLISHED FOR OPPOSITION
Wednesday, June 25, 2008NOTICE OF PUBLICATION
Wednesday, June 11, 2008LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, June 10, 2008TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, June 11, 2008ASSIGNED TO LIE
Wednesday, June 11, 2008APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, June 10, 2008TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 10, 2008CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 10, 2008TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, January 24, 2008REFUSAL PROCESSED BY IB
Monday, December 31, 2007NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, December 31, 2007REFUSAL PROCESSED BY MPU
Friday, December 28, 2007NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, December 27, 2007NON-FINAL ACTION WRITTEN
Thursday, December 27, 2007ASSIGNED TO EXAMINER
Friday, November 16, 2007NEW APPLICATION ENTERED IN TRAM
Thursday, November 15, 2007SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

immune treatment deficiencies autoimmune diseases biotechnologies plasma pharmaceutical preparations obtained